Submitted by Anonymous (not verified) on 1 August 2025 - 11:30
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 28, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 28, Status: Authorised